Nxera Pharma Co Eulerpool Haberleri

Nxera Pharma Co Eulerpool News

Nxera Pharma Co Hisse Haberleri

Nxera Pharma Co, dünya çapında birçok gazeteci ve yatırımcı tarafından takip edilmektedir. En güncel Nxera Pharma Co haberlerini burada bir araya getiriyoruz.

• 24 Eylül ·

  Yahoo
  Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia
• 13 Eylül ·

  Yahoo
  Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO
• 11 Eylül ·

  Yahoo
  Nxera Pharma’s Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
• 2 Eylül ·

  Yahoo
  Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
• 28 Ağustos ·

  Yahoo
  Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
• 9 Ağustos ·

  Yahoo
  Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024
• 9 Temmuz ·

  Yahoo
  Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results
• 9 Temmuz ·

  SeekingAlpha
  Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth
• 27 Haziran ·

  Yahoo
  Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
• 18 Haziran ·

  Yahoo
  Nxera Pharma Publishes its Annual and ESG Reports for the Year ended 31 December 2023